Evidence map›Paper›PMID 31746355›Full record

Trial reportMolecular medicine reports2020

Exploratory study on application of MALDI‑TOF‑MS to detect serum and urine peptides related to small cell lung carcinoma.

Panpan Lv, Zeyuan Liu, Bin Xu, Chuanhao Tang, Xiaoyan Li, Haifeng Qin, Shaoxing Yang, Hongjun Gao, Kun He, Xiaoqing Liu

Abstract readClinical Trial
In one paragraph

Trial report in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Panpan LvDepartment of Pulmonary Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, P.R. China.
Zeyuan LiuDepartment of Pulmonary Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, P.R. China.
Bin XuNational Center of Biomedical Analysis, Beijing 100069, P.R. China.
Chuanhao TangDepartment of Pulmonary Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, P.R. China.
Xiaoyan LiDepartment of Pulmonary Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, P.R. China.
Haifeng QinDepartment of Pulmonary Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, P.R. China.
Shaoxing YangDepartment of Pulmonary Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, P.R. China.
Hongjun GaoDepartment of Pulmonary Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, P.R. China.
Kun HeNational Center of Biomedical Analysis, Beijing 100069, P.R. China.
Xiaoqing LiuDepartment of Pulmonary Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Matrix‑assisted laser desorption/ionization time‑of‑flight mass spectrometry (MALDI‑TOF‑MS) was employed to analyze differential serum and urine peptides in patients with small cell lung cancer (SCLC) and healthy individuals, and SCLC diagnostic classification models were constructed. Serum and urine samples from 72 patients with SCLC, age‑ and gender‑matched with 72 healthy individuals, were divided into training and testing sets in a 3:1 ratio. Serum and urine peptides were extracted using copper ion‑chelating nanomagnetic beads, and mass spectra were obtained using MALDI‑TOF‑MS. Peptide spectra for the training set were analyzed, and the classification model was constructed using ClinProTools (CPT). The testing set was used for blinded model validation. For training‑set sera, 122 differential peptide signal peaks with a mass of 0.8‑10 kDa were observed, and 19 peptides showed significantly different expression [P<0.0005; area under curve (AUC) ≥0.80]. CPT screened 5 peptide peaks (0.8114, 0.83425, 1.86655, 4.11133 and 5.81192 kDa) to construct the classification model. The testing set was used for the blinded validation, which had 95.0% sensitivity and 90.0% specificity. For the training‑set urine, 132 differential peptide signal peaks with m/z ratios of 0.8‑10 kDa were observed, and 8 peptides had significantly different expression (P<0.0005; AUC ≥0.80). Then, 5 peaks (1.0724, 2.37692, 2.7554, 4.75475 and 4.7949 kDa) were used for classification model construction. The testing set was used for 36 blinded validation, which had 85.0% sensitivity and 80.0% specificity. Among the differential peptides, 3 had the same significant peaks at 2.3764, 0.8778 and 0.8616 kDa, identified as fibrinogen α, glucose‑6‑phosphate isomerase and cyclin‑dependent kinase‑1, respectively. The present study highlighted the differences that exist in serum and urine peptides between patients with SCLC and healthy individuals. Serum and urine peptide diagnostic classification models could be constructed using MALDI‑TOF‑MS, and showed high sensitivity and specificity.

Indexed as

Lung NeoplasmsNeoplasm ProteinsPeptidesSmall Cell Lung CarcinomaSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm ProteinsPeptidesMaldi-ToF-MSproteomicsserumsmall cell lung carcinomaurine

Identifiers

PMID31746355
PMCPMC6896340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.